Develops and markets AI-based cardiology diagnostics (Cardio Explorer®) for detecting coronary artery disease from routine data.
Exploris Health AG
Basel (CH)New on Amplifa
About Exploris Health
Exploris Health AG is a Swiss digital health and diagnostics company focused on cardiology. The company develops the Cardio Explorer®, an AI-supported software diagnostic that calculates an individualized, sex-specific probability of obstructive coronary artery disease from routine clinical chemistry data – without additional tests or sampling. The algorithmic approach is based on a machine-learned CAD model peer-reviewed and published since 2014 and was validated in European cohorts such as LURIC (AUC 0.87) and Maastricht (AUC 0.88). In 2023 the product received CE marking under the IVDD and has since been commercially deployed in Switzerland, Germany and the Netherlands, among other things integrated into Dedalus ORBIS and the Swiss electronic patient record. The company is certified to ISO 13485 (BSI) and ISO/IEC 27001 and is currently undergoing the EU IVDR conformity assessment. Customers and partners include the University Hospital of Basel, Maastricht UMC+, Roche and AOK Niedersachsen.
- Site
- Basel, Switzerland
- Processes
- AI-based diagnostics (Cardio Explorer® for coronary artery disease), Integration into hospital information systems (Dedalus ORBIS), Integration into the Swiss electronic patient record (EPR), Diagnostics from routine clinical chemistry data
- Materials
- Machine-learned CAD algorithm, Software as a Medical Device (SaMD), System integration (Dedalus ORBIS, EPR)
- Certificates
- ISO 13485, ISO/IEC 27001, EQUAL CARE (gender-equitable AI), CE Marking (IVDD), EQUAL CARE, EU IVDR (conformity assessment ongoing)
- Founded
- 2018
- Industries
- Medical technology / Digital Health, Cardiology, Diagnostics (IVD)
- 01
ML algorithm development (CAD diagnostics)
- 02
Clinical validation in European cohorts
- 03
Software development & product approval (CE/IVDR)
- 04
Integration into HIS/electronic patient records
- 05
Commercial distribution & study support
Technology & Algorithms
Machine-learned CAD algorithm
Core diagnostic algorithm for predicting obstructive coronary artery disease from routine laboratory data, published in the International Journal of Cardiology.
Software as a Medical Device (SaMD)
Cardio Explorer® is CE-marked diagnostic software under the IVDD with ongoing IVDR conformity assessment.
System integration (Dedalus ORBIS, EPR)
Native integration into hospital information systems and the Swiss electronic patient record without workflow changes.
Locations
Basel
CHHeadquarters: software development, regulatory, sales
- Materials
- Software as Medical Device
Products & Diagnostics
Inside the production
Industries
Additional services
Reference customers
Quality & Certifications
Exploris Health is certified to ISO 13485 (certified by BSI) and ISO/IEC 27001; the EQUAL CARE certification confirms gender-equitable AI. The EU IVDR conformity assessment is in progress.
| Evidence | Basel |
|---|---|
| ISO 13485 | |
| ISO/IEC 27001 | |
| CE Marking (IVDD) | |
| EQUAL CARE | |
| EU IVDR (conformity assessment ongoing) |
Company History
- 2014
Publication of the foundational ML-based CAD algorithm in the International Journal of Cardiology.
- 2018
Founding of Exploris Health AG in Switzerland; LURIC validation (AUC 0.87); Swiss Biolabs Award and 2nd prize in the IFAS Innovation Challenge.
- 2022
Pivotal intended-use validation in the Maastricht cohort with AUC 0.88 (BMJ Open).
- 2023
CE marking (IVDD) and commercial launch in Europe; independent Rb-82 PET/CT validation (EPMA Journal).
- 2024
DMEA nova Award ("Using AI to improve care"); EQUAL CARE certification; start of the AOK Niedersachsen study (ISRCTN67912485).
- 2025
ISO 13485 certification (BSI); Roche partnership; integration into Dedalus ORBIS and the Swiss electronic patient record (Post Sanela); recognized as a leading Swiss AI startup.
- 2026
ISO/IEC 27001 certification; completion of the AOK Niedersachsen study expected; EU IVDR conformity assessment ongoing.